SCHEMBL4464819

SCHEMBL4464819

Cc1c(O)c(CCC(C)CCCC(C)C)c(C)c2c1CCC1(CCC1)O2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
TTPA P49638 3/20 0.56
MAPT P10636 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
GSTP1 P09211 1/20 0.56
USP2 O75604 1/20 0.56
THRB P10828 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
NR1I2 O75469 2/20 0.47
ALOX5 P09917 1/20 0.44
PDE4A P27815 1/20 0.44
PDE3A Q14432 1/20 0.44
GSTO1 P78417 2/20 0.43
PSEN1 P49768 4/20 0.42
PTPN1 P18031 1/20 0.41
PDPK1 O15530 1/20 0.35
PHLPP1 O60346 1/20 0.35
AKT1 P31749 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467484 0.91 MAPT (0.46) LMNATTPAMAPTMEN1KMT2A
SCHEMBL5773566 0.77 MAPT (0.49) LMNATTPAMAPTMEN1KMT2A
SCHEMBL13409858 0.73 LMNA (0.77) LMNATTPAMAPTMEN1KMT2A
Alpha-Tochopherol SCHEMBL14315133 0.72 LMNA (1.00) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL14297170 0.72 LMNA (1.00) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL3059188 0.72 LMNA (1.00) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL16451007 0.72 LMNA (1.00) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL20817063 0.72 LMNA (1.00) LMNATTPAMAPTMEN1KMT2A
SCHEMBL2141831 0.72 LMNA (0.83) LMNATTPAMAPTMEN1KMT2A
SCHEMBL13068707 0.72 LMNA (0.91) LMNATTPAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP claimed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO claimed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US claimed
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 LMNA 1769/4885TTPA 255/4885MAPT 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.